1 reports of this reaction
7.7% of all KALI MURIATICUM reports
#8 most reported adverse reaction
MYELODYSPLASTIC SYNDROME is the #8 most commonly reported adverse reaction for KALI MURIATICUM, manufactured by Bestmade Natural Products. There are 1 FDA adverse event reports linking KALI MURIATICUM to MYELODYSPLASTIC SYNDROME. This represents approximately 7.7% of all 13 adverse event reports for this drug.
Patients taking KALI MURIATICUM who experience myelodysplastic syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELODYSPLASTIC SYNDROME is moderately reported among KALI MURIATICUM users, representing a notable but not dominant share of adverse events.
In addition to myelodysplastic syndrome, the following adverse reactions have been reported for KALI MURIATICUM:
The following drugs have also been linked to myelodysplastic syndrome in FDA adverse event reports:
MYELODYSPLASTIC SYNDROME has been reported as an adverse event in 1 FDA reports for KALI MURIATICUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELODYSPLASTIC SYNDROME accounts for approximately 7.7% of all adverse event reports for KALI MURIATICUM, making it a notable side effect.
If you experience myelodysplastic syndrome while taking KALI MURIATICUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.